Novel Interleukin-2 Variants and Bifunctional Fusion Molecules - Cugene Inc.
Summary
The European Patent Office published application EP3983001A2 for Cugene Inc. covering novel interleukin-2 variants and bifunctional fusion molecules, with inventors LI, Yue-Sheng, RUI, Lingyun, and XU, Jing. The application, published April 15, 2026, classifies under A61K 38/20 (cytokine preparations), G01N 33/53 and G01N 33/567 (immunoassay and binding assays), C07H 21/04 and C12P 21/04 (nucleic acid/protein compositions), and C07K 14/55 (interleukin proteins). The EPO designated 31 states including all EU member patent jurisdictions under the European Patent Convention.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The EPO published European patent application EP3983001A2 for Cugene Inc. covering novel interleukin-2 variants and bifunctional fusion molecules. The A2 designation indicates an application publication under the European Patent Convention, which makes the application publicly available 18 months after filing or priority date. This publication does not yet grant any enforceable patent rights.
Patent applicants, pharmaceutical researchers, and biotechnology companies working in cytokine therapeutics or fusion protein development should monitor this application's prosecution. Third parties may submit observations to the EPO during examination. A granted patent would provide European territorial protection, with the possibility of validation in individual contracting states.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL INTERLEUKIN-2 VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
Publication EP3983001A2 Kind: A2 Apr 15, 2026
Applicants
Cugene Inc.
Inventors
LI, Yue-Sheng, RUI, Lingyun, XU, Jing
IPC Classifications
A61K 38/20 20060101AFI20230831BHEP G01N 33/53 20060101ALI20230831BHEP G01N 33/567 20060101ALI20230831BHEP C07H 21/04 20060101ALI20230831BHEP C12P 21/04 20060101ALI20230831BHEP C07K 14/55 20060101ALI20230831BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.